Treatment with Elapegademase Restores Immunity in Infants with Adenosine Deaminase Deficient Severe Combined Immunodeficiency.

Elizabeth Daly Hicks Geoffrey Hall Michael S Hershfield Teresa K TarrantPawan BaliJohn W Sleasman Rebecca H Buckley Talal Mousallem

Published in: Journal of clinical immunology (2024)

Revcovi was safe and effective as initial therapy to restore immune function in these newly diagnosed infants with ADA-SCID, however, time course and degree of reconstitution varied. Revcovi dose may need to be optimized based on immune reconstitution, clinical status, and biochemical data.

Keyphrases

newly diagnosed
electronic health record
early onset
big data
stem cells
machine learning
protein kinase
deep learning
smoking cessation